First volunteer in Oxford COVID vaccine test dies in Brazil

A volunteer participating in clinical trials of the COVID-19 vaccine developed by Oxford University has died in Brazil, officials announced Wednesday, though media reports said he had received a placebo, not the test vaccine.

It is the first death reported in the various coronavirus vaccine trials taking place worldwide.

However, organizers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.

Media reports said the volunteer was a 28-year-old doctor working on the front lines of the pandemic who died of complications from COVID-19.

Brazilian newspaper Globo and international news agency Bloomberg said he was in the control group and had received a placebo rather than the test vaccine, citing sources close to the trials.

"Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue," Oxford said in a statement.

AstraZeneca said medical confidentiality meant it could not give details on any individual volunteer, but that independent review had "not led to any concerns about continuation of the ongoing study."

Brazil's national health regulator, Anvisa, confirmed it had been notified of the case on October 19.

The D'Or Teaching and Research Institute (IDOR), which is helping organize the tests in Brazil, said the independent review had "raised no doubts about the safety of the study, and recommended it continue."

Oxford and AstraZeneca previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.

Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.

Half the volunteers in the final-stage clinical trial -- a double-blind, randomized, controlled study -- receive a placebo, IDOR said.

Agence France-Presse